ETS1 and pleomorphic xanthoastrocytoma: In line with the data from our cell models, a residual tumor of an anaplastic PXA case operated during combination treatment of dabrafenib and the MEK-inhibitor trametinib had lost expression of ETS1, cyclin D1 and TERT (Additional file 3: Figure S8).